IN RE COORDINATED LATEX GLOVE LITIGATION
    
      121 Cal. Rptr.2d 301 (2002)
    
      NATURE OF THE CASE: McGinnis (P) appealed a judgment nothing withstanding the verdict in 
      her suit against Baxter (D) for a manufacturing defect in D's latex gloves.
    
      FACTS: P was the first in a series of plaintiffs to pursue a theory of product liability 
      that the latex gloves manufactured by D caused a serious, disabling, and potentially 
      life-threatening allergy to all forms of natural rubber latex. P claims D improperly 
      designed and manufactured gloves which caused this allergy by allowing excessive levels of 
      allergenic agents, latex proteins, to remain present on the surface of the gloves during 
      manufacture. Such agents may be greatly reduced or eliminated through washing and 
      chlorinating procedures in the design and manufacture of these gloves. D began to receive 
      reports around 1988-1989 that some health care workers commonly exposed to NRL products were 
      developing severe latex allergies. P was one of the victims. P experienced a 
      life-threatening anaphylactic reaction (respiratory distress, hives and other symptoms). She 
      was forced to leave health care work, has undergone emergency medical treatment for such 
      reactions, and must carry medication to treat them at all times, as her allergy is a 
      lifelong condition. P sued D on various products liability and negligence theories. The 
      matter went to jury trial on strict liability theories of manufacturing defect and failure 
      to warn of a defective product, and well as negligence through manufacture and failure to 
      warn. P presented evidence that additional washing and chlorination of the gloves would 
      reduce allergenic protein levels, while D presented evidence that these steps might lead to 
      defects in barrier protection such as pinholes, tearing, or a change in texture. From 1989 
      through 1991, D sold over 15 billion gloves, and received a total of 10 user complaints 
      describing type I severe allergic reactions to NRL gloves. In response to the problem, by 
      1992, D had implemented protein reduction techniques on all its production lines. By 1994, D 
      was requiring all its gloves to undergo a postcure rinse to reduce surface protein levels. 
      Later, a postcure protein leach procedure was added. D also made educational efforts about 
      NRL allergies for health care workers, presenting traveling seminars as part of its 
      marketing efforts. Around 1992-1994, it was advertising its gloves as 'The Right Choice,' 
      due to D's research and improvements in its manufacturing processes regarding allergens. In 
      March 1993, the FDA announced its plans to issue regulations requiring manufacturers to 
      state the latex content of medical devices such as gloves. Although the FDA was conducting 
      research in the area of latex allergies, it did not require warning labels on that subject 
      until 1996. Until 1998, due to concerns about the success of the AIDS, etc., universal 
      precautions requirement of glove usage, the FDA prohibited glove manufacturers from making 
      comparisons about protein levels of their product. P's claims did not include a strict 
      liability design defect cause of action as new case law prohibited her from presenting a 
      design defect theory based on consumer expectations. P did not present any alternative 
      design defect theory under a risk-benefit analysis. P went to the jury on her manufacturing 
      defect claim, failure to warn of a defect and/or through negligence, and negligent 
      manufacture and/or design. D argued that the protein level evidence offered by P had not 
      been placed in context with any applicable government requirements. The jury found that a 
      manufacturing defect had been proven and awarded P net compensatory damages of $ 886,921.20. 
      It found that D had been negligent but there had been no causation of her injuries through 
      negligence. D filed its motions for JNOV and new trial. It argued that with respect to the 
      manufacturing defect finding, no substantial evidence supported the verdict. It also argued 
      the causation findings were inconsistent and lacked support in the evidence, and excessive 
      damages had been awarded. D got the JNOV and P appealed. 
    
ISSUE:
RULE OF LAW:
HOLDING AND DECISION:
LEGAL ANALYSIS:
Get 
      free access to the entire content for Mac, PC or Online
for 2-3 days and free samples 
      of all kinds of products.
for 2-3 days and free samples of all kinds of products.
https://bsmsphd.com
© 2007-2016 Abn Study Partner
No comments:
Post a Comment